ARK Genomic Revolution ETF (0CQL)
LSE 
Summary
0CQL Chart
2 Actively Managed ETFs That Got Smoked by the S&P 500 Last Year
Low-cost passive index investing (in the S&P 500 or Nasdaq 100) has been key to impressive results in recent years.
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
Cathie Wood's Top Biotech Plays for February
Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.
ARK Genomic Revolution ETF Dividends
| ARKG ARKG 29 Dec 2021 Paid | Annual | $0.38 Per Share |
| ARKG ARKG 29 Dec 2020 Paid | Annual | $0.79 Per Share |
| ARKG ARKG 27 Dec 2019 Paid | Other | $1.05 Per Share |
| ARKG ARKG 27 Dec 2018 Paid | Other | $0.47 Per Share |
| ARKG ARKG 27 Dec 2017 Paid | Other | $0.33 Per Share |
ARK Genomic Revolution ETF Earnings
| ARKG ARKG 29 Dec 2021 Paid | Annual | $0.38 Per Share |
| ARKG ARKG 29 Dec 2020 Paid | Annual | $0.79 Per Share |
| ARKG ARKG 27 Dec 2019 Paid | Other | $1.05 Per Share |
| ARKG ARKG 27 Dec 2018 Paid | Other | $0.47 Per Share |
| ARKG ARKG 27 Dec 2017 Paid | Other | $0.33 Per Share |
ARK Genomic Revolution ETF (0CQL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ARK Genomic Revolution ETF ever had a stock split?
ARK Genomic Revolution ETF Profile
| - Industry | - Sector | - CEO | LSE Exchange | US00214Q3020 ISIN |
| United States Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
The fund is a cutting-edge investment vehicle focusing on the burgeoning field of genomics, operating as an actively-managed exchange-traded fund (ETF). It seeks to capitalize on the transformative potential of genomics across various sectors, including healthcare, information technology, materials, energy, and consumer discretionary. By investing primarily in both domestic and foreign equity securities of companies at the forefront of the genomics revolution, the fund aims to offer investors unique exposure to this dynamic and rapidly evolving industry. Despite its concentrated theme, the fund maintains a broad perspective by integrating firms from multiple sectors that are instrumental in advancing genomics-related technologies and applications. It is non-diversified, indicating a focused investment strategy in companies specifically selected for their relevance to the genomics revolution.
Products and Services
- Equity Securities of Genomics Revolution Companies
This product is the centerpiece of the fund's investment strategy, comprising a significant portion of its assets in domestic and foreign equity securities of companies leading the genomics revolution. By focusing on sectors such as healthcare, information technology, materials, energy, and consumer discretionary, the fund targets entities that are integral to the advancement of genomics. This includes firms engaged in genetic sequencing, gene editing, biotechnological innovation, and other areas that contribute to the evolution of genomics.
Contact Information
